American Association for Cancer Research
15357163mct130066-sup-fig_4.pdf (233.11 kB)

Supplementary Figure 4 from Apigenin Sensitizes Colon Cancer Cells to Antitumor Activity of ABT-263

Download (233.11 kB)
journal contribution
posted on 2023-04-03, 13:51 authored by Huanjie Shao, Kai Jing, Esraa Mahmoud, Haihong Huang, Xianjun Fang, Chunrong Yu

PDF - 233KB, Supplementary Figure S4. ABT-263 treatment resulted in upregulation of Mcl-1.



Apigenin is an edible plant-derived flavonoid that shows modest antitumor activities in vitro and in vivo. Apigenin treatment resulted in cell growth arrest and apoptosis in various types of tumors by modulating several signaling pathways. In the present study, we evaluated interactions between apigenin and ABT-263 in colon cancer cells. We observed a synergistic effect between apigenin and ABT-263 on apoptosis of colon cancer cells. ABT-263 alone induced limited cell death while upregulating expression of Mcl-1, a potential mechanism for the acquired resistance to ABT-263. The presence of apigenin antagonized ABT-263–induced Mcl-1 upregulation and dramatically enhanced ABT-263–induced cell death. Meanwhile, apigenin suppressed AKT and ERK activation. Inactivation of either AKT or ERK by lentivirus-transduced shRNA or treatment with specific small-molecule inhibitors of these pathways enhanced ABT-263–induced cell death, mirroring the effect of apigenin. Moreover, the combination response was associated with upregulation of Bim and activation of Bax. Downregulation of Bax eliminated the synergistic effect of apigenin and ABT-263 on cell death. Xenograft studies in SCID mice showed that the combined treatment with apigenin and ABT-263 inhibited tumor growth by up to 70% without obvious adverse effects, while either agent only inhibited around 30%. Our results demonstrate a novel strategy to enhance ABT-263–induced antitumor activity in human colon cancer cells by apigenin via inhibition of the Mcl-1, AKT, and ERK prosurvival regulators. Mol Cancer Ther; 12(12); 2640–50. ©2013 AACR.